Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland

被引:3
|
作者
Kelleher, Dan [1 ]
Barry, Luke [2 ]
McGowan, Bernie [3 ]
Doherty, Edel [1 ]
Carey, John J. [3 ]
Kane, David [4 ,5 ]
机构
[1] Natl Univ Ireland, Hlth Econ & Policy Anal Ctr, Galway, Ireland
[2] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland
[3] Natl Univ Ireland, Sch Med, Galway, Ireland
[4] Trinity Coll Dublin, Dept Med Rheumatol, Dublin, Ireland
[5] HSE, Natl Clin Programme Rheumatol, Dublin, Ireland
关键词
Primary care; rheumatoid arthritis; budget; care pathways; referrals; CARE; COMBINATION; VALIDATION; SENIORS; COST;
D O I
10.1093/rap/rkaa059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the budget impact from the perspective of the Irish health-care system attributable to a reconfiguration in the diagnostic care pathway for patients with suspected RA by adopting an early identification and referral model (EIM). Methods The budget impact model evaluated the total health-care use and costs attributable to an EIM to diagnose patients with suspected RA relative to the reference scenario of current practice. The modelling also assessed a primary outcome of effect, which examined how many patients can be diagnosed by a rheumatologist within 3 months of symptom onset. The budget impact analysis model was estimated over a 5-year time frame. Results The EIM generated a cost saving for the Irish health-care system of (sic)237 547 over the time frame relative to current practice. The cost savings were realized owing to a reduction in the number of general practitioner (GP) visits of 18 790 and a reduction in diagnostic tests carried out by GPs. The results showed that 1027 (510%) more patients were diagnosed within 3 months of symptom onset in the EIM compared with current practice. Conclusion This paper has presented an alternative rheumatologist-led service design that can be used in diagnosing patients with suspected RA. The rheumatologist-led service provision detailed in this study has the potential simultaneously to reduce demand for primary care services and to improve the health outcomes of patients. The use of an EIM sees rheumatologist activity incorporate patient demand.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] TOFACITINIB IN ADULT PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: BUDGET IMPACT ANALYSIS
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2017, 20 (09) : A529 - A529
  • [2] BUDGET IMPACT ANALYSIS OF TOFACITINIB IN ADULT RHEUMATOID ARTHRITIS PATIENTS IN IRAQ
    AlAni, N.
    Sunna, N.
    Ghorab, A.
    AlJabban, A.
    Awad, N.
    Mohamed, O.
    VALUE IN HEALTH, 2019, 22 : S167 - S167
  • [3] Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis
    Benucci, M.
    Iannazzo, S.
    Zaniolo, O.
    Sabadini, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : 722 - 727
  • [4] What factors account for referral delays for patients with suspected rheumatoid arthritis?
    Suter, LG
    Fraenkel, L
    Holmboe, ES
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (02): : 300 - 305
  • [5] NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
    Iannazzo, S.
    Giuliani, G.
    Zaniolo, O.
    Sacchi, V
    Pradelli, L.
    VALUE IN HEALTH, 2008, 11 (06) : A540 - A540
  • [6] A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY
    Iannazzo, S.
    Zaniolo, O.
    Giuliani, G.
    VALUE IN HEALTH, 2010, 13 (07) : A305 - A305
  • [7] An Analysis of Laboratory Characteristics of Patients with Suspected Rheumatoid Arthritis
    Ciftci, Ihsan Hakki
    Asik, Gulsah
    Toktas, Hasan
    Cufall, Davut
    Dundar, Umit
    Karakece, Engin
    TURKISH JOURNAL OF RHEUMATOLOGY, 2013, 28 (01) : 27 - 31
  • [8] BUDGET IMPACT ANALYSIS OF GOLIMUMAB IN ADULT RHEUMATOID ARTHRITIS PATIENTS IN KINGDOM OF SAUDI ARABIA
    Al Jedai, A.
    AL-Mudaiheem, H.
    Pathak, P.
    Awad, N.
    Mohamed, O.
    Alghanim, N.
    Hussain, W.
    Qamar, A.
    Alama, T.
    VALUE IN HEALTH, 2019, 22 : S47 - S47
  • [9] BUDGET IMPACT ANALYSIS OF INTRODUCING TOFACITINIB FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN HONG KONG
    Li, X.
    Chan, E. W.
    Wong, I. C.
    VALUE IN HEALTH, 2018, 21 : S80 - S80
  • [10] BUDGET IMPACT ANALYSIS OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS (RA) IN COLOMBIA
    Gamboa, O.
    Barbosa-Tovar, D.
    Leon, E.
    Gil, A. M.
    Lozano, T.
    Latorre, M. C.
    VALUE IN HEALTH, 2014, 17 (03) : A43 - A44